Results 81 to 90 of about 1,042 (177)

Biologics in the Management of Sever Atopic Dermatitis [PDF]

, 2023
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases, it is presented with heterogeneous clinical phenotypes that can alter by severity, age, and ethnic background.
Al Abadie, Mohammed, Al Abadie, Sami, Sharara, Zinah   +2 more
core  

Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis

International Journal of Dermatology, EarlyView.
ABSTRACT Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative.
Andrea Lancz, Fanni Adél Meznerics, Renáta Árok, Anna Sára Lengyel, Bence Szabó, Péter Hegyi, Norbert Kiss, András Bánvölgyi   +7 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: living update [PDF]

The evidence- and consensus-based living guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual.
Arents, B., Aszodi, N., Barbarot, S., Bieber, T., Brough, H. A., Calzavara‐Pinton, P., Christen‐Zaech, S., Deleuran, M., Dittmann, M., Flohr, C., Fosse, N., Gerbens, L. A. A., Gieler, U., Girolomoni, G., Gregoriou, S., Gáspár, K., Holland, S., Kinberger, M., Mortz, C. G., Nast, A., Nygaard, U., Rehbinder, E. M., Ring, J., Rossi, M., Serra‐Baldrich, E., Simon, D., Szalai, Z. Z., Szepietowski, J. C., Torrelo, A., Werfel, T., Werner, R. N., Wollenberg, Andreas   +31 more
core   +3 more sources

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source

The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl, Claudia Zeidler, Joyce Loewenthal, Svenja Royeck, Matthias Augustin, Robert Bissonnette, Sarina Elmariah, Brian S. Kim, Laurent Misery, Hiroyuki Murota, Hong Liang Tey, Elke Weisshaar, Gil Yosipovitch, Franz J. Legat, Adam Reich, Martin Metz, Sonja Ständer   +16 more
wiley   +1 more source

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer, Sarina B. Elmariah, Shawn G. Kwatra, Gil Yosipovitch, Andrew E. Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K. Jabbar‐Lopez, Liliana Ulianov, Christophe Piketty, Jonathan I. Silverberg   +10 more
wiley   +1 more source

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

New England Journal of Medicine, 2020
Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic ...
Kenji, Kabashima, Takayo, Matsumura, Hiroshi, Komazaki, Makoto, Kawashima   +3 more
openaire   +2 more sources

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source